A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis (DR-TB) and provide access to effective cure and prevention of DR-TB throughout the world.

Over ten million people will develop tuberculosis (TB) in the world this year; over 500,000 of these will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and regimens involving new TB drugs in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter news click here!


Developments in MDR-TB

U.S. FDA approves new pediatric formulation of SIRTURO® (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant TB

Posted on 03 Jun 2020

NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided.

MDR-TB Epidemiology Research Fellowship

Posted on 29 Apr 2020

The Harvard Medical School Blavatnik Institute of Global Health & Social Medicine is seeking candidates for a research fellowship in multidrug-resistant tuberculosis epidemiology. More information and application can be found here.

For more news, click here.